CS MEDICA Group Achieves Complete Registration of CANNASEN® CBD-Infused
Medical Devices in Israel

EQS-Ad-hoc: CS MEDICA A/S / Key word(s): Regulatory Approval
CS MEDICA Group Achieves Complete Registration of CANNASEN® CBD-Infused
Medical Devices in Israel

17-Jun-2024 / 15:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Strategic Milestone Achieved as CANNORDIC, a CS MEDICA Subsidiary, Navigates
Regulatory Challenges to Expand Global Footprint

CS MEDICA Group, a leader in innovative substance-based medical devices
containing bioactive CBD, is proud to announce the successful completion of
the product registration process for its entire CANNASEN® portfolio of
CBD-infused medical devices in Israel under its subsidiary CANNORDIC. This
significant milestone, achieved in partnership with Forbe Healthcare Ltd.,
sets a new standard for medical device compliance and innovation in the
region, as it is the first complete product portfolio of over-the-counter
products containing CBD that has been approved for sale by Israel's Ministry
of Health.

In August 2022, CANNORDIC, the manufacturing and commercial entity of CS
MEDICA Group, initiated a distribution agreement with Forbe Healthcare Ltd.,
known for its strong distribution network across pharmacies and hospitals.
The agreement covers the distribution of CANNASEN® medical device products
in Israel and Palestine. It includes the distribution of 852,000 units
valued at DKK 37.1 million over the next 3.5 years.

The strategic agreement was to launch multiple medical devices, starting
with the CANNASEN® Pain Patch. After an 8-9 month product registration
process at Israel's Ministry of Health, it became the first ever
over-the-counter (OTC) product with CBD in Israel. Due to the new market
conditions, it launched in December 2024 with a 2-month delay and has been
well-received.

The registration process for the remaining products faced delays due to
regulatory changes and regional conflicts. However, the US FDA approval
previously obtained significantly facilitated the resumption and successful
completion of the product registration process for the entire portfolio.

Lone Henriksen, CEO of CS MEDICA Group, comments: ""Despite delays due to
the complex regulatory environment and the unfortunate ongoing regional
challenges, the complete product registration of our 6 medical devices
reflects the resilience and strategic focus of CANNORDIC and Forbe
HealthCare. These factors required detailed navigation of regulatory
pathways and adaptation to changing market conditions, contributing to the
extended approval timeline."

As CANNORDIC and Forbe Healthcare finalize preparations for production and
market launch, they are dedicated to adapting their strategy to reflect
current market conditions, ensuring the responsible delivery of high-quality
healthcare solutions.

Forbe Healthcare Ltd. is committed to providing high-end healthcare products
and services, striving to meet consumers' daily needs with innovative,
high-quality, evidence-based solutions. With an extensive distribution
network across all pharmacies and hospitals in Israel and Palestine, Forbe
Healthcare Ltd. plays a crucial role in introducing groundbreaking medical
devices to the market.

CS MEDICA Group, a Danish MedTech pioneer, specializes in developing
evidence-based, CBD-integrated treatments for pain management, autoimmune
and stress-related disorders. With a focus on patient-centric care, our
products range from innovative R&D to registered over-the-counter
substance-based medical devices and dermaceuticals. Our flagship CANNASEN®
brand, alongside our own-label solutions, exemplifies our dedication to
safe, high-quality treatments for both human and veterinary health globally.
The company is listed on Spotlight Stock Market in Stockholm (symbol:
"CSMED"). For more information, visit cs-medica.com and LinkedIn.

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech
company specializing in innovative substance-based medical devices
containing bioactive CBD. Our dedication to enhancing lives by integrating
innovation, science, technology, and natural cannabis compounds positions it
as a pioneer in the medical technology industry. The company ensures robust
research, development, manufacturing, compliance, data insights, and
commercialization processes with strong partners globally.


End of Inside Information

---------------------------------------------------------------------------

17-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        CS MEDICA A/S
                   Indiakaj 10,2
                   2100 Copenhagen
                   Denmark
   Phone:          +45 70707337
   E-mail:         info@cs-medica.com
   Internet:       https://www.cs-medica.com
   ISIN:           DK0061668225
   WKN:            A3CYEQ
   Listed:         Regulated Unofficial Market in Frankfurt, Munich,
                   Stuttgart
   EQS News ID:    1926767

End of Announcement EQS News Service
---------------------------------------------------------------------------

1926767 17-Jun-2024 CET/CEST